Business
Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024
2024 OIS Retina and ARVO meetings are being held in Seattle, Washington BEDFORD, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc.
About this update from Ocular Therapeutix, Inc.
[{"type":"text","content":"2024 OIS Retina and ARVO meetings are being held in Seattle, Washington\nBEDFORD, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, announced multiple presentations at the Ophthalmology Innovation Source (OIS) Retina 2024 (May 4th) and the Association for Research in Vision and Ophthalmology (ARVO) 2024 meetings (May 5-9th) being held in Seattle, Washington. Presentations at OIS Retina 2024: Session Title: “Spotlight on Drug Delivery”Session Date/Time: Saturday, May 4th, 11:15 AM – 12:00 PM PDTOcular Presentation: 11:34 – 11:41 AM PDTPresenter: Sanjay Nayak, MBBS, PhD, Chief Strategy Officer Panel Title: “The View from the Street”Session Date/Time: Saturday, May 4th at 5:00 – 5:30 PM PDTModerator: Pravin U. Dugel, MD, Executive Chairman, President and Chief Executive Officer Presentations at ARVO 2024: Oral Presentation: Pharmacodynamic efficacy of second-generation intravitreal axitinib implant (AXPAXLI) in a VEGF challenge rabbit modelSession Date/Time: Thursday, May 9th 3:30 – 3:45 PM PDTLocation: Yakima 1 - Seattle Convention Center - Arch BuildingPresenter: Chuck Blizzard, Vice President, Research & Development Poster Title: Long-term safety of repeated intravitreal axitinib implant (AXPAXLI) administrations in non-human primatesPoster Board #: B0299Session Date/Time: Monday, May 6th 8:30 – 10:15 AM PDTLocation: Exhibit Hall – Seattle Convention CenterPresenter: Chintan Patel, PhD, Associate Director, Nonclinical Development Poster Title: Optimized pharmacokinetic profile of intravitreal axitinib implant (AXPAXLI): a comparison of first- and second-generation implantsPoster Board #: B0300Session Date/Time: Monday, May 6th 8:30 – 10:15 AM PDTLocation: Exhibit Hall – Seattle Convention CenterPresenter: Madhoosudan Patil, PhD, Senior Scientist About Ocular Therapeutix, Inc.Ocular Therapeutix, Inc. is a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet A...